CABA Cabaletta Bio

Cabaletta Bio to Present at Multiple August Investor Conferences

Cabaletta Bio to Present at Multiple August Investor Conferences

PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming August investor conferences:

  • BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 1:00 p.m. ET.
  • Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 8:35 a.m. ET.
  • 40th Annual Canaccord Genuity Growth Conference on Wednesday, August 12, 2020 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the News and Events section of the company’s website at . Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTesTM phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see . The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit .

Contacts:

Anup Marda

Chief Financial Officer

Sarah McCabe

Stern Investor Relations, Inc.

EN
03/08/2020

Underlying

CABACabaletta Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cabaletta Bio

 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provid...

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update – Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gravis – ...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Pricing of Public Offering of Securities

Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in li...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces Proposed Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certa...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patie...

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all imm...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Participate in the Jefferies Global Healthcare Confer...

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events sect...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch